CommentGLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
References (10)
- et al.
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Lancet Diabetes Endocrinol
(2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Diabetes Obes Metab
(2016)- et al.
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
Endocr Rev
(2011) - et al.
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
Diabet Med
(2010) - et al.
Energy balance after sodium-glucose cotransporter 2 inhibition
Diabetes Care
(2015)
Cited by (17)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
2018, Kidney InternationalCitation Excerpt :Of course, as with any glucose-lowering medication, the advantages, side-effect profiles, and costs should be considered to tailor individualized therapy, as discussed in the following. For combination therapies and kidney protection, SGLT2 inhibitors and GLP1RA agents may be used together due to their different and unique mechanisms of action for both glycemic and nonglycemic effects.115 Moreover, it is likely that these 2 classes reduce albuminuria via different mechanisms, with SGLT2 inhibitors acting on predominant hemodynamic pathways and glucagon-like peptide-1 receptors agonists (GLP1RAs) via nonhemodynamic anti-inflammatory and oxidant mechanisms.
Novel therapies for diabetic kidney disease
2018, Kidney International SupplementsCitation Excerpt :Third, among the glucose-lowering agents, SGLT2is lead to a proximal natriuresis, as described above. GLP-1 RAs and DPP-4 inhibitors, on the other hand, induce natriuretic effects through proximal and distal mechanisms, respectively, which may lead to additive plasma volume depletion when used in combination.86 Further benefits may result from additive effects on HbA1c, weight reduction, and blood pressure lowering, as shown in the Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy (DURATION-8) trial, leading to further potential renal and cardiovascular protection.87
Circadian Regulation of Apolipoproteins in the Brain: Implications in Lipid Metabolism and Disease
2023, International Journal of Molecular SciencesNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
2023, Annual Review of MedicineHigh-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
2022, Clinics and Practice